|
Patent landscape, scope, and claims: |
Analysis of United States Patent 11,026,939: Lenvatinib Mesylate Formulations
This report analyzes United States Patent 11,026,939, titled "Lenvatinib Mesylate Formulations," focusing on its scope, claims, and the surrounding patent landscape. The patent, granted to Eisai R&D Management Co., Ltd. on June 8, 2021, describes specific mesylate salt forms of lenvatinib and methods for their preparation and use.
What is the Core Innovation Claimed by Patent 11,026,939?
Patent 11,026,939 claims novel crystalline forms of lenvatinib mesylate, designated as Form A and Form B. These crystalline forms exhibit specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and thermogravimetric analysis (TGA) data, which are claimed to provide advantages over previously known forms. The patent also claims methods for preparing these specific crystalline forms and pharmaceutical compositions containing them.
Specifically, the patent defines Form A by its XRPD pattern exhibiting characteristic peaks at specific 2-theta angles, and Form B by its distinct XRPD pattern. The claimed advantages of these forms include improved stability and processability, which are critical for pharmaceutical manufacturing and drug product quality.
What are the Key Claims Covered by the Patent?
The patent contains several independent and dependent claims covering various aspects of the claimed inventions. Key claims include:
- Claim 1: A crystalline form of lenvatinib mesylate designated as Form A, characterized by its XRPD pattern having specific diffraction peaks. This is a foundational claim defining a specific solid-state form.
- Claim 11: A crystalline form of lenvatinib mesylate designated as Form B, characterized by its XRPD pattern having specific diffraction peaks. This claim defines a second distinct crystalline form.
- Claim 19: A pharmaceutical composition comprising a crystalline form of lenvatinib mesylate as claimed in any one of claims 1 to 18, and a pharmaceutically acceptable carrier. This claim extends the patent protection to the final drug product.
- Claim 20: A method for preparing crystalline Form A of lenvatinib mesylate, comprising crystallizing lenvatinib mesylate from a solvent system comprising an alcohol and water. This claim protects specific manufacturing processes for the claimed forms.
- Dependent Claims: Numerous dependent claims further define these forms by specifying additional characterization data (e.g., DSC, TGA), impurity profiles, or specific process parameters, thereby narrowing the scope while strengthening the protection for specific embodiments.
These claims aim to protect the novel solid-state forms of lenvatinib mesylate, their preparation, and their use in pharmaceutical compositions. The breadth of the claims is significant as it covers not only the specific crystalline forms but also compositions containing them and methods of their production, impacting generic manufacturers seeking to produce lenvatinib products.
What is the Chemical and Pharmaceutical Significance of Lenvatinib?
Lenvatinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor. It acts by inhibiting the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRA), KIT, and RET proto-oncogenes.
Lenvatinib is approved for the treatment of various types of cancer, including:
- Unresectable hepatocellular carcinoma (HCC) [1].
- Advanced renal cell carcinoma (RCC) in combination with everolimus or as monotherapy following prior anti-angiogenic therapy [1].
- Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine treatment [1].
The mesylate salt form of lenvatinib is the active pharmaceutical ingredient (API) used in approved lenvatinib products. The development of specific crystalline forms of this API is crucial for ensuring drug product consistency, stability, bioavailability, and manufacturability. Different crystalline forms (polymorphs) can have distinct physical and chemical properties, such as solubility, dissolution rate, and hygroscopicity, which directly influence the drug's performance and shelf life. Patent 11,026,939 targets these specific, advantageous crystalline forms.
What are the Key Properties of the Claimed Crystalline Forms?
The patent describes Lenvatinib Mesylate Form A and Form B as having distinct physical properties.
Lenvatinib Mesylate Form A
Form A is characterized by its XRPD pattern exhibiting major diffraction peaks at approximately the following 2-theta values (°): 8.5, 11.1, 15.9, 17.9, 20.5, 22.5, 25.6, and 27.2.
The patent also provides DSC data for Form A, showing an endotherm with a peak temperature around 192.0°C. TGA data indicates a weight loss of approximately 0.3% between 25°C and 100°C, and a major exothermic peak around 194.3°C.
Lenvatinib Mesylate Form B
Form B is characterized by its XRPD pattern exhibiting major diffraction peaks at approximately the following 2-theta values (°): 9.1, 11.7, 14.0, 16.5, 18.5, 21.6, 23.5, and 26.2.
The patent also provides DSC data for Form B, showing an endotherm with a peak temperature around 185.8°C. TGA data indicates a weight loss of approximately 1.4% between 25°C and 100°C, and a major exothermic peak around 188.5°C.
These specific characterizations are crucial for defining the novel crystalline forms and distinguishing them from other potential forms or amorphous lenvatinib mesylate. The claimed stability and processability advantages are directly linked to these defined physical characteristics.
What is the Patent Landscape for Lenvatinib?
The patent landscape for lenvatinib is complex, involving multiple patents covering the compound itself, its various salt forms, specific crystalline polymorphs, pharmaceutical compositions, and methods of treatment. Patent 11,026,939 specifically targets crystalline forms of lenvatinib mesylate.
Key patents in the lenvatinib landscape, in addition to 11,026,939, include:
- Composition of Matter Patents: These are typically the earliest and broadest patents, covering the lenvatinib molecule itself. The original composition of matter patent for lenvatinib and its therapeutic uses would have an earlier priority date. These are crucial for establishing the initial market exclusivity.
- Salt and Polymorph Patents: Patents like 11,026,939 fall into this category. They claim specific salt forms (e.g., mesylate) and, importantly, specific crystalline forms (polymorphs) of the API. These patents can extend market exclusivity beyond the initial composition of matter patent.
- Formulation Patents: These patents cover specific ways the drug is formulated into a dosage form (e.g., tablets, capsules), including excipients and manufacturing processes for the final drug product.
- Method of Treatment Patents: These patents claim specific uses of lenvatinib for treating particular diseases or patient populations.
Key Companies and Players:
- Eisai Co., Ltd.: The primary innovator and holder of the original lenvatinib patents, including patents related to its mesylate salt and specific crystalline forms. Eisai markets lenvatinib under the brand name Lenvima®.
- Generic Manufacturers: Companies that develop and seek to market generic versions of lenvatinib. These companies must navigate the existing patent landscape, aiming to launch their products after key patents expire or by challenging existing patents. Major generic players include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Hetero Drugs Ltd.
Patent Expiration and Generic Entry:
The market exclusivity for lenvatinib is primarily governed by the expiration dates of its key patents. The expiration of the composition of matter patents typically provides the first opportunity for generic entry. However, secondary patents, such as those covering specific crystalline forms (like 11,026,939), formulations, and methods of treatment, can extend market protection for the innovator.
Generic companies often challenge these secondary patents to secure earlier market entry. Litigation related to patent infringement and validity is common in the pharmaceutical sector and plays a significant role in shaping the lenvatinib market. For instance, generic manufacturers may seek to develop non-infringing crystalline forms or argue that the claims of patents like 11,026,939 are either invalid or not infringed by their proposed product.
The expiration of Patent 11,026,939 will be a critical milestone, potentially allowing generic versions of lenvatinib mesylate that utilize the specific Form A or Form B crystalline structures to enter the market, provided other relevant patents have also expired or been successfully challenged.
What are the Implications of Patent 11,026,939 for R&D and Investment?
For R&D Departments
- Freedom to Operate (FTO) Analysis: R&D teams developing new lenvatinib formulations or manufacturing processes must conduct thorough FTO analyses to ensure they do not infringe on the claims of Patent 11,026,939. This includes analyzing the crystalline form of lenvatinib mesylate used, its preparation method, and the final pharmaceutical composition.
- Polymorph Screening: Innovator companies may have already secured patents for the most stable and advantageous crystalline forms. New R&D efforts may focus on discovering novel polymorphs, solvates, or amorphous forms of lenvatinib mesylate that are not covered by existing patents, or on developing alternative salt forms.
- Process Development: If a company intends to use lenvatinib mesylate Form A or Form B, they must develop manufacturing processes that do not fall under the scope of Claim 20 and its dependent claims. This might involve exploring different crystallization solvents, conditions, or purification steps.
For Investment Decisions
- Market Exclusivity Period: Investors need to assess the remaining patent life of key lenvatinib patents, including 11,026,939. The expiration date of this patent will influence the timeline for generic competition and its potential impact on Lenvima® sales.
- Litigation Risk: The potential for patent litigation surrounding lenvatinib patents is a significant risk factor. Investors should consider the history of patent disputes involving Eisai and lenvatinib and the likelihood of future challenges to patents like 11,026,939.
- Generic Market Potential: For investors in generic pharmaceutical companies, understanding the patent landscape, including the claims and expiration of patents like 11,026,939, is crucial for assessing the potential market entry timelines and profitability of generic lenvatinib products. The existence of patent protection for specific crystalline forms can delay generic entry until those patents expire or are invalidated.
- Innovation Opportunities: Investors can identify opportunities in companies developing novel lenvatinib delivery systems, combination therapies, or next-generation RTK inhibitors that circumvent existing patent protections.
The specific crystalline forms claimed in Patent 11,026,939 represent a critical layer of intellectual property protection for Eisai. Its expiration will be a key determinant for the timing and nature of generic market entry for lenvatinib.
Key Takeaways
- United States Patent 11,026,939 protects specific crystalline forms of lenvatinib mesylate, designated as Form A and Form B, characterized by their unique XRPD patterns and thermal properties.
- The patent also claims methods for preparing these crystalline forms and pharmaceutical compositions containing them, providing broad protection for lenvatinib mesylate API and drug products.
- These crystalline forms are claimed to offer improved stability and processability, critical for pharmaceutical manufacturing and drug efficacy.
- The patent landscape for lenvatinib is complex, with Patent 11,026,939 representing a secondary layer of protection extending beyond the original composition of matter patents.
- The expiration of Patent 11,026,939 will impact generic manufacturers' ability to produce lenvatinib mesylate using the claimed crystalline forms.
- R&D and investment decisions must account for the FTO related to these claimed crystalline forms and the remaining patent exclusivity period.
Frequently Asked Questions
-
When does United States Patent 11,026,939 expire?
The expiration date for a U.S. utility patent is typically 20 years from the filing date, subject to potential patent term extensions and adjustments. For Patent 11,026,939, filed on February 27, 2019, the standard expiration would be February 27, 2039, without considering any potential extensions or adjustments. However, market entry for generic products also depends on the expiration of other relevant patents, particularly the original composition of matter patents.
-
Can a generic company produce lenvatinib mesylate if they do not use Form A or Form B as described in the patent?
Yes, a generic company may be able to produce lenvatinib mesylate if they can demonstrate that their product does not infringe on the claims of Patent 11,026,939. This could involve developing a different crystalline form (polymorph), an amorphous form, or a different salt of lenvatinib that is not covered by the patent's claims. Thorough freedom-to-operate analysis is essential.
-
Does Patent 11,026,939 cover all possible forms of lenvatinib mesylate?
No, Patent 11,026,939 specifically covers Form A and Form B of lenvatinib mesylate and their preparation methods. It does not necessarily cover all other conceivable crystalline forms, amorphous forms, or other salt forms of lenvatinib that may exist or be developed.
-
What are the potential consequences if a generic company infringes on Patent 11,026,939?
If a generic company is found to infringe on Patent 11,026,939, the patent holder (Eisai) could file an infringement lawsuit. Remedies for infringement can include injunctions to prevent the sale of the infringing product, monetary damages (including lost profits or reasonable royalties), and attorney fees in exceptional cases.
-
Are there other patents that protect the lenvatinib mesylate drug product currently on the market?
Yes, lenvatinib products are protected by a portfolio of patents. These typically include patents covering the lenvatinib molecule itself (composition of matter), specific salt forms, specific crystalline forms (like those in 11,026,939), pharmaceutical formulations, and methods of treating specific diseases. Patent 11,026,939 is one of several such secondary patents.
Citations
[1] U.S. Food & Drug Administration. (n.d.). LENVIMA® (lenvatinib) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207022s027lbl.pdf
More… ↓
⤷ Start Trial
|
